IL289934B2 - Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids - Google Patents

Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids

Info

Publication number
IL289934B2
IL289934B2 IL289934A IL28993422A IL289934B2 IL 289934 B2 IL289934 B2 IL 289934B2 IL 289934 A IL289934 A IL 289934A IL 28993422 A IL28993422 A IL 28993422A IL 289934 B2 IL289934 B2 IL 289934B2
Authority
IL
Israel
Prior art keywords
compound
acid
lipid
filtered
mrna
Prior art date
Application number
IL289934A
Other languages
English (en)
Hebrew (he)
Other versions
IL289934B (en
IL289934A (en
Original Assignee
Acuitas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acuitas Therapeutics Inc filed Critical Acuitas Therapeutics Inc
Publication of IL289934A publication Critical patent/IL289934A/en
Publication of IL289934B publication Critical patent/IL289934B/en
Publication of IL289934B2 publication Critical patent/IL289934B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/08—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to an acyclic carbon atom of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/10—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to an acyclic carbon atom of a carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33303—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group
    • C08G65/33306—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group acyclic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
IL289934A 2014-06-25 2015-06-05 Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids IL289934B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462016839P 2014-06-25 2014-06-25
PCT/US2015/034496 WO2015199952A1 (en) 2014-06-25 2015-06-05 Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids

Publications (3)

Publication Number Publication Date
IL289934A IL289934A (en) 2022-03-01
IL289934B IL289934B (en) 2022-12-01
IL289934B2 true IL289934B2 (en) 2023-04-01

Family

ID=53433312

Family Applications (6)

Application Number Title Priority Date Filing Date
IL289934A IL289934B2 (en) 2014-06-25 2015-06-05 Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
IL316479A IL316479A (en) 2014-06-25 2015-06-05 Novel lipids and lipid nanoparticle compositions for nucleic acid delivery
IL298516A IL298516B2 (en) 2014-06-25 2015-06-05 Novel lipids and lipid nanoparticle compositions for nucleic acid delivery
IL249718A IL249718A0 (en) 2014-06-25 2016-12-22 Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
IL260772A IL260772B (en) 2014-06-25 2018-07-25 Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
IL277448A IL277448B (en) 2014-06-25 2020-09-17 Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids

Family Applications After (5)

Application Number Title Priority Date Filing Date
IL316479A IL316479A (en) 2014-06-25 2015-06-05 Novel lipids and lipid nanoparticle compositions for nucleic acid delivery
IL298516A IL298516B2 (en) 2014-06-25 2015-06-05 Novel lipids and lipid nanoparticle compositions for nucleic acid delivery
IL249718A IL249718A0 (en) 2014-06-25 2016-12-22 Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
IL260772A IL260772B (en) 2014-06-25 2018-07-25 Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
IL277448A IL277448B (en) 2014-06-25 2020-09-17 Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids

Country Status (17)

Country Link
US (6) US9738593B2 (OSRAM)
EP (3) EP3766916B1 (OSRAM)
JP (5) JP6594421B2 (OSRAM)
CN (2) CN106795096B (OSRAM)
AU (4) AU2015280499B2 (OSRAM)
CA (2) CA3179824A1 (OSRAM)
ES (2) ES2931832T3 (OSRAM)
HR (1) HRP20221536T1 (OSRAM)
HU (1) HUE060907T2 (OSRAM)
IL (6) IL289934B2 (OSRAM)
LT (1) LT3766916T (OSRAM)
PL (1) PL3766916T3 (OSRAM)
PT (1) PT3766916T (OSRAM)
RS (1) RS63848B1 (OSRAM)
SI (1) SI3766916T1 (OSRAM)
SM (1) SMT202200502T1 (OSRAM)
WO (1) WO2015199952A1 (OSRAM)

Families Citing this family (551)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3981427T1 (sl) 2010-08-31 2022-08-31 Glaxosmithkline Biologicals S.A. Pegilirani liposomi za dostavo imunogen-kodirajoče RNA
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
EP2717893B1 (en) 2011-06-08 2019-05-08 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mrna delivery
DK2972360T3 (en) 2013-03-15 2018-05-22 Translate Bio Inc SYNERGISTIC IMPROVEMENT OF DELIVERY OF NUCLEIC ACIDS THROUGH MIXED FORMULATIONS
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
ES3009962T3 (en) 2014-04-23 2025-03-31 Modernatx Inc Nucleic acid vaccines
CN106795096B (zh) 2014-06-25 2020-05-29 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
EP3289083A4 (en) * 2015-04-27 2018-12-19 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
HRP20240865T1 (hr) 2015-06-29 2024-10-11 Acuitas Therapeutics Inc. Lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina
ES2910425T3 (es) 2015-09-17 2022-05-12 Modernatx Inc Compuestos y composiciones para la administración intracelular de agentes terapéuticos
CN114606267A (zh) 2015-09-28 2022-06-10 北卡罗来纳-查佩尔山大学 逃避抗体的病毒载体的方法和组合物
JP2018532777A (ja) * 2015-10-22 2018-11-08 モデルナティーエックス， インコーポレイテッド 癌ワクチン
CA3002922A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
AU2016343803B2 (en) * 2015-10-28 2021-04-29 Acuitas Therapeutics, Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
AU2016366978B2 (en) 2015-12-10 2022-07-28 Modernatx, Inc. Compositions and methods for delivery of therapeutic agents
JP7065036B2 (ja) * 2015-12-17 2022-05-11 モダーナティエックス・インコーポレイテッド メチルマロニルＣｏＡムターゼをコードするポリヌクレオチド
SMT202200252T1 (it) * 2015-12-22 2022-07-21 Modernatx Inc Composti e composizioni per il rilascio intracellulare di agenti
US20210206818A1 (en) 2016-01-22 2021-07-08 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
US10457631B2 (en) 2016-04-06 2019-10-29 Ohio State Innovation Foundation Biodegradable amino-ester nanomaterials for nucleic acid delivery
WO2017177169A1 (en) 2016-04-08 2017-10-12 Rana Therapeutics, Inc. Multimeric coding nucleic acid and uses thereof
US20190167811A1 (en) 2016-04-13 2019-06-06 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
ES2871537T3 (es) 2016-05-09 2021-10-29 Astrazeneca Ab Nanopartículas lipídicas que comprenden agentes antiinflamatorios lipófilos y métodos de uso de las mismas
CN109195621A (zh) 2016-05-18 2019-01-11 莫得纳特斯公司 编码白细胞介素12(il12)的多核苷酸及其用途
WO2017201328A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE
US20190298657A1 (en) 2016-05-18 2019-10-03 Modernatx, Inc. Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
JP2019519601A (ja) 2016-05-18 2019-07-11 モダーナティエックス・インコーポレイテッドＭｏｄｅｒｎａＴＸ， Ｉｎｃ． 急性間欠性ポルフィリン症の治療のためのポルホビリノゲン脱アミノ酵素をコードするポリヌクレオチド
KR102533456B1 (ko) * 2016-05-18 2023-05-17 모더나티엑스, 인크. 릴랙신을 인코딩하는 폴리뉴클레오타이드
MA45036A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour la citrine pour le traitement de la citrullinémie de type 2
MA45050A (fr) * 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour la lipoprotéine lipase destinés au traitement de l'hyperlipidémie
MA45053A (fr) * 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour un régulateur de conductance transmembranaire de fibrose kystique pour le traitement de la fibrose kystique
US12128113B2 (en) * 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
WO2017201348A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
EP3842530A1 (en) 2016-06-13 2021-06-30 Translate Bio, Inc. Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency
JP2019525901A (ja) 2016-06-14 2019-09-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 脂質ナノ粒子の安定化製剤
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
EP3532103B1 (en) 2016-10-26 2025-12-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
MX2019004913A (es) * 2016-10-26 2019-09-16 Curevac Ag Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
RU2765874C2 (ru) 2016-10-26 2022-02-04 МОДЕРНАТиЭкс, ИНК. Матричные рибонуклеиновые кислоты для усиления иммунных ответов и способы их применения
US20190274968A1 (en) 2016-10-27 2019-09-12 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
EP3315125A1 (en) 2016-10-31 2018-05-02 Silence Therapeutics (London) Ltd Lipid nanoparticle formulation
ES2928358T3 (es) * 2016-11-08 2022-11-17 Univ Ramot Lípidos catiónicos para el suministro de ácidos nucleicos y preparación de los mismos
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
CN110167587A (zh) * 2016-11-11 2019-08-23 摩登纳特斯有限公司 流感疫苗
US11103578B2 (en) 2016-12-08 2021-08-31 Modernatx, Inc. Respiratory virus nucleic acid vaccines
WO2018107026A1 (en) * 2016-12-09 2018-06-14 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
WO2018115527A2 (en) 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
EP3558355A2 (en) 2016-12-23 2019-10-30 CureVac AG Henipavirus vaccine
EP3558354A1 (en) 2016-12-23 2019-10-30 CureVac AG Lassa virus vaccine
BR112019014314A2 (pt) 2017-01-11 2020-02-18 The Trustees Of The University Of Pennsylvania Composição, e, método de indução de uma resposta imune adaptativa contra vírus zika.
EP3576780A1 (en) 2017-02-01 2019-12-11 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
US20200368162A1 (en) * 2017-02-24 2020-11-26 Modernatx, Inc. Nucleic Acid-Based Therapy of Muscular Dystrophies
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
CA3055653A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
SI3596041T1 (sl) * 2017-03-15 2023-02-28 Modernatx, Inc. Spojina in sestavki za intracelično dostavljanje terapevtskih sredstev
EP3609534A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. WIDE SPECTRUM INFLUENZA VIRUS VACCINE
MA47787A (fr) * 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
CA3056133A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Crystal forms of amino lipids
US11752206B2 (en) * 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
EP3596112A2 (en) 2017-03-17 2020-01-22 Newcastle University Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
CA3050614A1 (en) 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
US20200038499A1 (en) * 2017-03-22 2020-02-06 Modernatx, Inc. Rna bacterial vaccines
JP2020513824A (ja) 2017-03-24 2020-05-21 キュアバック アーゲー Ｃｒｉｓｐｒ関連タンパク質をコードする核酸、及びその使用
MA48047A (fr) 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
WO2018191657A1 (en) * 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
WO2018191719A1 (en) * 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipid delivery of therapeutic agents to adipose tissue
JP7464954B2 (ja) 2017-04-27 2024-04-10 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｃ型肝炎ウイルスに対するヌクレオシド修飾ｍＲＮＡ－脂質ナノ粒子系統ワクチン
EP4410317A3 (en) 2017-04-28 2024-10-30 Acuitas Therapeutics Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
CA3063531A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
EP3625246A1 (en) 2017-05-18 2020-03-25 ModernaTX, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
WO2018232006A1 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Polynucleotides encoding coagulation factor viii
EP3638678B1 (en) 2017-06-14 2025-12-03 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
EP3641834B1 (en) 2017-06-19 2023-10-04 Translate Bio, Inc. Messenger rna therapy for the treatment of friedreich's ataxia
EP4494652A3 (en) 2017-07-04 2025-05-14 CureVac SE Cancer rna-vaccine
WO2019036008A1 (en) 2017-08-16 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
EP3668834B1 (en) 2017-08-17 2024-10-02 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036030A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
US11542225B2 (en) 2017-08-17 2023-01-03 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11602557B2 (en) 2017-08-22 2023-03-14 Cure Vac SE Bunyavirales vaccine
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
WO2019089828A1 (en) 2017-10-31 2019-05-09 Acuitas Therapeutics, Inc. Lamellar lipid nanoparticles
MA50801A (fr) 2017-11-22 2020-09-30 Modernatx Inc Polynucléotides codant pour la phénylalanine hydroxylase pour le traitement de la phénylcétonurie
MA51306A (fr) 2017-12-20 2020-10-28 Translate Bio Inc Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
MX2020006843A (es) 2017-12-27 2020-09-03 Takeda Pharmaceuticals Co Nanoparticula de lipido que contiene acido nucleico y uso de la misma.
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
WO2019152557A1 (en) 2018-01-30 2019-08-08 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells
BR112020020266A2 (pt) 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
EP3774852A1 (en) 2018-04-03 2021-02-17 Stridebio, Inc. Antibody-evading virus vectors
EA202092362A1 (ru) 2018-04-03 2021-01-11 Страйдбайо, Инк. Вирусные векторы для нацеливания на ткани глаза
WO2019193183A2 (en) 2018-04-05 2019-10-10 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
EP4227319B1 (en) 2018-04-17 2025-11-26 CureVac SE Novel rsv rna molecules and compositions for vaccination
WO2019222277A1 (en) 2018-05-15 2019-11-21 Translate Bio, Inc. Subcutaneous delivery of messenger rna
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
US12076439B2 (en) 2018-05-24 2024-09-03 Translate Bio, Inc. Thioester cationic lipids
JP2021525743A (ja) 2018-05-30 2021-09-27 トランスレイト バイオ， インコーポレイテッド リン酸エステルカチオン性脂質
CN112424214A (zh) 2018-05-30 2021-02-26 川斯勒佰尔公司 包含甾族部分的阳离子脂质
MA52766A (fr) 2018-05-30 2021-04-14 Translate Bio Inc Lipides cationiques vitaminiques
AU2019277361B2 (en) 2018-05-30 2025-04-24 Translate Bio, Inc. Messenger RNA vaccines and uses thereof
PL3805198T3 (pl) 2018-06-08 2024-02-12 Fujifilm Corporation Związek, jego sól i cząstki lipidowe
EP3807413B1 (en) 2018-06-18 2025-05-21 Research Institute at Nationwide Children's Hospital Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
EP3813874A1 (en) 2018-06-27 2021-05-05 CureVac AG Novel lassa virus rna molecules and compositions for vaccination
EP3813798A1 (en) 2018-06-28 2021-05-05 AstraZeneca AB Exosome extracellular vesicles and methods of use
EP3826608A1 (en) 2018-07-23 2021-06-02 Translate Bio, Inc. Dry power formulations for messenger rna
JP6997862B2 (ja) * 2018-08-21 2022-02-10 株式会社東芝 生分解性化合物、脂質粒子、脂質粒子を含む組成物、およびキット
US11357726B2 (en) 2018-08-29 2022-06-14 Translate Bio, Inc. Process of preparing mRNA-loaded lipid nanoparticles
EP3849617A1 (en) 2018-09-14 2021-07-21 Translate Bio, Inc. Composition and methods for treatment of methylmalonic acidemia
AU2019338535A1 (en) 2018-09-14 2021-04-15 Modernatx, Inc. Methods and compositions for treating cancer using mRNA therapeutics
US12263248B2 (en) 2018-09-19 2025-04-01 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
MA53650A (fr) 2018-09-19 2021-07-28 Modernatx Inc Lipides peg et leurs utilisations
AU2019345067A1 (en) 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
IL322436A (en) 2018-09-21 2025-09-01 Acuitas Therapeutics Inc Systems and methods for producing lipid nanoparticles and liposomes
EP3867225A1 (en) 2018-10-18 2021-08-25 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
US20210381006A1 (en) 2018-10-18 2021-12-09 Takeda Pharmaceutical Company Limited Method for activation/proliferation of t cells
WO2020081933A1 (en) 2018-10-19 2020-04-23 Translate Bio, Inc. Pumpless encapsulation of messenger rna
EP3876994A2 (en) 2018-11-09 2021-09-15 Translate Bio, Inc. Peg lipidoid compounds
WO2020097376A1 (en) 2018-11-09 2020-05-14 Translate Bio, Inc. Multi-peg lipid compounds
EP3876914A2 (en) 2018-11-09 2021-09-15 Translate Bio, Inc. Messenger rna therapy for treatment of ocular diseases
BR112021008974A2 (pt) 2018-11-09 2021-08-03 Translate Bio, Inc. lipídios de 2,5-dioxopiperazina com frações éster, tioéster, dissulfeto e anidrido intercaladas
US20220096612A1 (en) 2018-11-12 2022-03-31 Translatebioinc Methods for inducing immune tolerance
AU2019383413A1 (en) 2018-11-21 2021-05-27 Translate Bio, Inc. Cationic lipid compounds and compositions thereof for use in the delivery of messenger RNA
TW202039534A (zh) 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
AU2019410737A1 (en) 2018-12-21 2021-06-10 CureVac SE RNA for malaria vaccines
AU2020206109B2 (en) 2019-01-07 2024-12-19 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
US11453639B2 (en) 2019-01-11 2022-09-27 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
CA3125511A1 (en) 2019-02-08 2020-08-13 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
BR112021018776A2 (pt) 2019-03-21 2021-11-30 Stridebio Inc Vetores de vírus adenoassociado recombinante
US20220177423A1 (en) 2019-04-18 2022-06-09 Translate Bio, Inc. Cystine cationic lipids
ES2972014T3 (es) 2019-04-22 2024-06-10 Translate Bio Inc Lípidos catiónicos de tioéster
JP2022530043A (ja) * 2019-04-25 2022-06-27 インテリア セラピューティクス，インコーポレーテッド イオン化可能なアミン脂質及び脂質ナノ粒子
WO2020227085A1 (en) 2019-05-03 2020-11-12 Translate Bio, Inc. Di-thioester cationic lipids
WO2020227537A1 (en) 2019-05-07 2020-11-12 Modernatx, Inc Differentially expressed immune cell micrornas for regulation of protein expression
AU2020268388A1 (en) 2019-05-07 2021-12-02 Modernatx, Inc. Polynucleotides for disrupting immune cell activity and methods of use thereof
US20220226244A1 (en) 2019-05-31 2022-07-21 Translate Bio, Inc. Macrocyclic lipids
JP7744011B2 (ja) 2019-06-07 2025-09-25 スクライブ・セラピューティクス・インコーポレイテッド 操作されたｃａｓｘシステム
EP3986452A1 (en) 2019-06-18 2022-04-27 CureVac AG Rotavirus mrna vaccine
JP7724161B2 (ja) 2019-06-21 2025-08-15 トランスレイト バイオ， インコーポレイテッド トリシンおよびクエン酸脂質
WO2020257611A1 (en) 2019-06-21 2020-12-24 Translate Bio, Inc. Cationic lipids comprising an hydroxy moiety
KR20220078557A (ko) 2019-07-08 2022-06-10 트랜슬레이트 바이오 인코포레이티드 개선된 mrna 로딩된 지질 나노입자 및 이의 제조 방법
EP3999642A1 (en) 2019-07-19 2022-05-25 Flagship Pioneering Innovations VI, LLC Recombinase compositions and methods of use
US12144871B2 (en) 2019-07-23 2024-11-19 Translate Bio, Inc. Stable compositions of MRNA-loaded lipid nanoparticles and processes of making
US20220280639A1 (en) * 2019-07-31 2022-09-08 Modernatx, Inc. Compositions and methods for delivery of rna interference agents to immune cells
WO2021026358A1 (en) 2019-08-07 2021-02-11 Moderna TX, Inc. Compositions and methods for enhanced delivery of agents
HRP20241255T1 (hr) * 2019-08-14 2024-12-06 Acuitas Therapeutics, Inc. Poboljšane lipidne nanočestice za isporuku nukleinskih kiselina
CA3144902A1 (en) 2019-08-14 2022-01-19 Andreas Thess Rna combinations and compositions with decreased immunostimulatory properties
CN114929205B (zh) 2019-09-06 2024-09-03 世代生物公司 包括末端封闭式dna和可切割脂质的脂质纳米颗粒组合物及其使用方法
CN120423969A (zh) 2019-09-19 2025-08-05 摩登纳特斯有限公司 用于治疗剂的细胞内递送的支链尾端脂质化合物和组合物
US20220411361A1 (en) * 2019-09-19 2022-12-29 Modernatx, Inc. Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
MX2022003394A (es) 2019-09-20 2022-06-22 Translate Bio Inc Arnm que codifica cftr manipulado.
AU2020355000A1 (en) 2019-09-23 2022-03-17 Omega Therapeutics, Inc. Compositions and methods for modulating apolipoprotein B (APOB) gene expression
JP2022548399A (ja) 2019-09-23 2022-11-18 オメガ セラピューティクス， インコーポレイテッド 肝細胞核因子４－アルファ（ＨＮＦ４α）遺伝子発現をモジュレートするための組成物および方法
WO2021076805A1 (en) 2019-10-15 2021-04-22 Moderna TX, Inc. Mrnas encoding immune modulating polypeptides and uses thereof
CN114787180A (zh) 2019-10-17 2022-07-22 斯特里迪比奥公司 用于治疗c型尼曼-匹克病的腺相关病毒载体
US20210145860A1 (en) 2019-10-21 2021-05-20 Translate Bio, Inc. Compositions, methods and uses of messenger rna
DK4328309T3 (da) * 2019-11-15 2025-08-18 Fujifilm Corp Lipidsammensætning
WO2021102411A1 (en) 2019-11-22 2021-05-27 Generation Bio Co. Ionizable lipids and nanoparticle compositions thereof
US20230051811A1 (en) 2019-12-20 2023-02-16 Translate Bio, Inc Rectal delivery of messenger rna
US12053551B2 (en) 2019-12-20 2024-08-06 Translate Bio, Inc. Process of preparing mRNA-loaded lipid nanoparticles
JP2023510308A (ja) 2020-01-10 2023-03-13 モデルナティエックス インコーポレイテッド 寛容原性樹状細胞を作る方法
WO2021142245A1 (en) 2020-01-10 2021-07-15 Translate Bio, Inc. Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
US20230130155A1 (en) 2020-01-30 2023-04-27 Modernatx, Inc. Mrnas encoding metabolic reprogramming polypeptides and uses thereof
CA3160511A1 (en) 2020-02-04 2021-08-12 Susanne RAUCH Coronavirus vaccine
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
JP7744354B2 (ja) 2020-02-25 2025-09-25 トランスレイト バイオ， インコーポレイテッド Ｍｒｎａ担持脂質ナノ粒子を調製する改善された方法
JP2023517326A (ja) 2020-03-11 2023-04-25 オメガ セラピューティクス， インコーポレイテッド フォークヘッドボックスｐ３（ｆｏｘｐ３）遺伝子発現をモジュレートするための組成物および方法
CN115667531A (zh) 2020-03-24 2023-01-31 世代生物公司 非病毒DNA载体和其用于表达戈谢（Gaucher）治疗剂的用途
MX2022011805A (es) 2020-03-24 2023-01-11 Generation Bio Co Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con factor ix.
JP7746280B2 (ja) 2020-03-27 2025-09-30 ジェネレーション バイオ カンパニー 新規脂質及びそれらのナノ粒子組成物
WO2021198157A1 (en) 2020-03-30 2021-10-07 BioNTech SE Rna compositions targeting claudin-18.2
IL297084A (en) 2020-04-09 2022-12-01 Suzhou Abogen Biosciences Co Ltd Lipid nanoparticle compounds
CN113874507A (zh) 2020-04-09 2021-12-31 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
WO2021207710A2 (en) 2020-04-09 2021-10-14 Verve Therapeutics, Inc. Base editing of angptl3 and methods of using same for treatment of disease
WO2021213924A1 (en) 2020-04-22 2021-10-28 BioNTech SE Coronavirus vaccine
US20230190954A1 (en) 2020-05-07 2023-06-22 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
EP4146342A1 (en) 2020-05-07 2023-03-15 Translate Bio, Inc. Improved compositions for cftr mrna therapy
AU2021269042A1 (en) 2020-05-07 2023-02-02 Translate Bio, Inc. Optimized nucleotide sequences encoding SARS-CoV-2 antigens
US20230226219A1 (en) 2020-05-14 2023-07-20 Translate Bio, Inc. Peg lipidoid compounds
CA3183399A1 (en) 2020-05-15 2021-11-18 Translate Bio, Inc. Lipid nanoparticle formulations for mrna delivery
CN116322760A (zh) 2020-05-20 2023-06-23 旗舰创业创新第六有限责任公司 冠状病毒抗原组合物及其用途
IL298363A (en) 2020-05-20 2023-01-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and uses thereof
IL298539A (en) 2020-05-29 2023-01-01 Flagship Pioneering Innovations Vi Llc Trem compositions and methods relating thereto
EP4158032A2 (en) 2020-05-29 2023-04-05 Flagship Pioneering Innovations VI, LLC Trem compositions and methods relating thereto
CA3170740A1 (en) 2020-05-29 2021-12-02 Curevac Ag Nucleic acid based combination vaccines
MX2022016332A (es) 2020-06-15 2023-04-03 Res Inst Nationwide Childrens Hospital Administracion de vectores de virus adenoasociados para distrofias musculares.
WO2025056938A1 (en) 2023-09-11 2025-03-20 BioNTech SE Rna compositions for delivery of incretin agents
KR20230030588A (ko) 2020-06-30 2023-03-06 쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 지질 화합물 및 지질 나노입자 조성물
US20240307556A1 (en) 2020-07-02 2024-09-19 Maritime Therapeutics, Inc. Compositions and methods for reverse gene therapy
WO2022008613A1 (en) 2020-07-08 2022-01-13 Janssen Sciences Ireland Unlimited Company Rna replicon vaccines against hbv
FI4182297T3 (fi) 2020-07-16 2025-12-05 Acuitas Therapeutics Inc Kationisia lipidejä käytettäväksi lipidinanohiukkasissa
BR112023001648A2 (pt) 2020-07-27 2023-04-04 Anjarium Biosciences Ag Moléculas de dna de fita dupla, veículo de entrega e método para preparar uma molécula de dna com extremidade em grampo
EP4172194A1 (en) 2020-07-31 2023-05-03 CureVac SE Nucleic acid encoded antibody mixtures
CA3189854A1 (en) 2020-08-06 2022-02-10 Modernatx, Inc. Compositions for the delivery of payload molecules to airway epithelium
US12104163B2 (en) 2020-08-19 2024-10-01 Sarepta Therapeutics, Inc. Adeno-associated virus vectors for treatment of Rett syndrome
CN114391008B (zh) 2020-08-20 2024-05-03 苏州艾博生物科技有限公司 脂质化合物和脂质纳米颗粒组合物
CN114073677B (zh) * 2020-08-20 2023-06-09 深圳深信生物科技有限公司 一种脂质纳米颗粒
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
EP4157344A2 (en) 2020-08-31 2023-04-05 CureVac SE Multivalent nucleic acid based coronavirus vaccines
IL300947A (en) 2020-09-03 2023-04-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and uses thereof
CZ2020529A3 (cs) * 2020-09-23 2022-03-30 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
KR20230083323A (ko) 2020-10-06 2023-06-09 트랜슬레이트 바이오 인코포레이티드 개선된 지질 나노입자 공정 및 제형화
IL301973A (en) 2020-10-12 2023-06-01 Translate Bio Inc Improved process of preparing mrna-loaded lipid nanoparticles
WO2022081548A1 (en) 2020-10-12 2022-04-21 Translate Bio, Inc. Improved process of preparing ice-based lipid nanoparticles
MX2023004371A (es) * 2020-10-14 2023-07-26 George Mason Res Foundation Inc Lípidos ionizables, y métodos de fabricación y uso de los mismos.
CN116710074A (zh) * 2020-10-14 2023-09-05 乔治梅森研究基金会公司 脂质纳米颗粒制造方法和由其衍生的组合物
US20220160633A1 (en) 2020-11-09 2022-05-26 Translate Bio, Inc. Compositions for delivery of codon-optimized mrna
KR20230113580A (ko) 2020-11-25 2023-07-31 트랜슬레이트 바이오 인코포레이티드 안정한 액체 지질 나노입자 제형
WO2022112855A1 (en) * 2020-11-27 2022-06-02 Guangzhou Ribobio Co., Ltd Lipid compound and the composition thereof
US20230242474A1 (en) * 2020-11-27 2023-08-03 Guangzhou Ribobio Co., Ltd Lipid compound and the composition thereof
GB2616584A (en) 2020-12-03 2023-09-13 Scribe Therapeutics Inc Engineered class 2 type V CRISPR systems
CA3205569A1 (en) 2020-12-22 2022-06-30 CureVac SE Rna vaccine against sars-cov-2 variants
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
WO2022135993A2 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
US20240175020A1 (en) 2020-12-23 2024-05-30 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
EP4267740A1 (en) 2020-12-28 2023-11-01 Arcturus Therapeutics, Inc. Transcription activator-like effector nucleases (talens) targeting hbv
EP4277929A1 (en) 2021-01-14 2023-11-22 Translate Bio, Inc. Methods and compositions for delivering mrna coded antibodies
WO2022152109A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
WO2022152141A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Polymer conjugated lipid compounds and lipid nanoparticle compositions
CA3208267A1 (en) * 2021-01-15 2022-07-21 Pfizer Inc. Methods for producing of lipids
US20240102065A1 (en) 2021-01-27 2024-03-28 CureVac SE Method of reducing the immunostimulatory properties of in vitro transcribed rna
CN112961065B (zh) * 2021-02-05 2023-03-14 嘉晨西海(杭州)生物技术有限公司 一种可电离脂质分子及其制备方法及其在制备脂质纳米颗粒的应用
MX2023009195A (es) * 2021-02-05 2023-12-08 Immorna Hangzhou Biotechnology Co Ltd Molecula lipida ionizable, metodo de preparacion de la misma, y aplicacion de la misma en la preparacion de nanoparticula lipida.
CN112961091B (zh) * 2021-02-07 2022-06-17 深圳深信生物科技有限公司 一种氨基脂质化合物及其制备方法和用途
KR20230145124A (ko) 2021-02-08 2023-10-17 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 불포화된 덴드리머 조성물, 관련된 제형, 및 이의 사용 방법
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
WO2022204219A1 (en) 2021-03-22 2022-09-29 Recode Therapeutics, Inc. Compositions and methods for targeted delivery to cells
MX2023011243A (es) 2021-03-23 2023-12-14 Recode Therapeutics Inc Composiciones de polinucleotidos, formulaciones relacionadas y metodos de uso de los mismos.
AU2022245247A1 (en) * 2021-03-24 2023-10-05 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
US20250268994A1 (en) 2021-03-25 2025-08-28 Translate Bio, Inc. Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof
JP2024511206A (ja) 2021-03-26 2024-03-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
WO2022207862A2 (en) 2021-03-31 2022-10-06 Curevac Ag Syringes containing pharmaceutical compositions comprising rna
AU2022249357A1 (en) 2021-04-01 2023-10-12 Modernatx, Inc. Methods for identification and ratio determination of rna species in multivalent rna compositions
WO2022214026A1 (zh) * 2021-04-08 2022-10-13 厦门赛诺邦格生物科技股份有限公司 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用
WO2022215036A1 (en) 2021-04-08 2022-10-13 Vaxthera Sas Coronavirus vaccine comprising a mosaic protein
CN115197079A (zh) * 2021-04-08 2022-10-18 厦门赛诺邦格生物科技股份有限公司 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用
US20250073351A1 (en) * 2021-04-19 2025-03-06 Translate Bio, Inc. Improved compositions for delivery of mrna
JP2024517427A (ja) 2021-04-20 2024-04-22 アンジャリウム バイオサイエンシズ エージー アミロ－α－１，６－グルコシダーゼ、４－α－グルカノトランスフェラーゼをコードするＤＮＡ分子の組成物、その作製の方法、及びその使用の方法
US20240216535A1 (en) 2021-04-27 2024-07-04 Generation Bio Co. Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
CA3216585A1 (en) 2021-04-27 2022-11-03 Nathaniel SILVER Non-viral dna vectors expressing therapeutic antibodies and uses thereof
CN117279888A (zh) * 2021-04-28 2023-12-22 富士胶片株式会社 化合物或其盐、脂质颗粒及药物组合物
WO2022233880A1 (en) 2021-05-03 2022-11-10 Curevac Ag Improved nucleic acid sequence for cell type specific expression
JP7664392B2 (ja) 2021-05-24 2025-04-17 スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド 脂質化合物及び脂質ナノ粒子組成物
CN114276535B (zh) * 2021-06-30 2022-06-21 天津键凯科技有限公司 聚乙二醇脂质及其应用
JP2024527541A (ja) 2021-07-01 2024-07-25 トランスレイト バイオ， インコーポレイテッド Ｍｒｎａの送達のための組成物
EP4362957A1 (en) 2021-07-01 2024-05-08 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
EP4367242A2 (en) 2021-07-07 2024-05-15 Omega Therapeutics, Inc. Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
WO2023001286A1 (zh) * 2021-07-23 2023-01-26 天津键凯科技有限公司 一种多元甘醇修饰的脂质化合物及其制备方法和应用
EP4377457A1 (en) 2021-07-26 2024-06-05 Flagship Pioneering Innovations VI, LLC Trem compositions and uses thereof
WO2023010133A2 (en) 2021-07-30 2023-02-02 Tune Therapeutics, Inc. Compositions and methods for modulating expression of frataxin (fxn)
WO2023010135A1 (en) 2021-07-30 2023-02-02 Tune Therapeutics, Inc. Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
US20240342206A1 (en) 2021-07-30 2024-10-17 CureVac SE mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES
US20240401006A1 (en) 2021-08-04 2024-12-05 Moderna TX, Inc. Mrnas encoding chimeric metabolic reprogramming polypeptides and uses thereof
WO2023023055A1 (en) 2021-08-16 2023-02-23 Renagade Therapeutics Management Inc. Compositions and methods for optimizing tropism of delivery systems for rna
CN117999355A (zh) 2021-08-24 2024-05-07 生物技术欧洲股份公司 体外转录技术
CA3229889A1 (en) 2021-09-03 2023-03-09 Glaxosmithkline Biologicals Sa Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids
IL309505A (en) 2021-09-03 2024-02-01 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
JP2024533865A (ja) 2021-09-14 2024-09-12 レナゲード セラピューティクス マネージメント インコーポレイテッド 環状脂質及びその使用方法
TW202325263A (zh) 2021-09-14 2023-07-01 美商雷納嘉德醫療管理公司 非環狀脂質及其使用方法
JP2024534428A (ja) 2021-09-17 2024-09-20 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 環状ポリリボヌクレオチドを生成するための組成物及び方法
CA3234127A1 (en) 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
AU2022361755A1 (en) 2021-10-08 2024-04-04 Pfizer Inc. Immunogenic lnp compositions and methods thereof
AR127312A1 (es) 2021-10-08 2024-01-10 Suzhou Abogen Biosciences Co Ltd Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
CN116064598B (zh) 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
TW202327646A (zh) 2021-10-15 2023-07-16 美商輝瑞大藥廠 Rna分子
MX2024004618A (es) 2021-10-18 2024-07-12 Flagship Pioneering Innovations Vi Llc Composiciones y metodos para purificar polirribonucleotidos.
US20250295755A1 (en) 2021-10-22 2025-09-25 Sail Biomedicines, Inc. Mrna vaccine composition
CA3235362A1 (en) 2021-10-26 2023-05-04 Astrazeneca Ab Novel lipids for delivery of nucleic acid segments
US20250027108A1 (en) 2021-10-29 2025-01-23 CureVac SE Improved circular rna for expressing therapeutic proteins
WO2023077170A1 (en) 2021-11-01 2023-05-04 Modernatx, Inc. Polynucleotides encoding integrin beta-6 and methods of use thereof
WO2023081756A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
WO2023081526A1 (en) 2021-11-08 2023-05-11 Orna Therapeutics, Inc. Lipid nanoparticle compositions for delivering circular polynucleotides
AU2022388747A1 (en) 2021-11-10 2024-06-20 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
CN118829423A (zh) 2021-11-12 2024-10-22 摩登纳特斯有限公司 用于将有效载荷分子递送至气道上皮的组合物
CN118829625A (zh) 2021-11-16 2024-10-22 赛欧生物医药股份有限公司 新型可电离脂质和脂质纳米颗粒以及它们的使用方法
KR20240108475A (ko) 2021-11-18 2024-07-09 아스트라제네카 아베 핵산 세그먼트의 전달을 위한 신규한 지질
JP2024542260A (ja) * 2021-11-22 2024-11-13 セイル バイオメディシンズ インコーポレイテッド 新規イオン化可能な脂質および脂質ナノ粒子ならびにそれらを使用する方法
CN118488834A (zh) 2021-11-23 2024-08-13 赛欧生物医药股份有限公司 细菌源性脂质组合物和其用途
KR20240125931A (ko) 2021-11-24 2024-08-20 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 수두-대상포진 바이러스 면역원 조성물 및 이의 용도
US20250352638A1 (en) 2021-11-24 2025-11-20 Flagship Pioneering Innovations Vi, Llc Coronavirus immunogen compositions and their uses
MX2024006440A (es) 2021-11-24 2024-08-19 Flagship Pioneering Innovations Vi Llc Composiciones inmunogenicas y sus usos.
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US12129223B2 (en) 2021-12-16 2024-10-29 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
CA3242399A1 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Fluorinated cationic lipids for use in lipid nanoparticles
JP2024546950A (ja) 2021-12-16 2024-12-26 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子に用いるフッ化カチオン性脂質
PE20241621A1 (es) 2021-12-17 2024-08-07 Pfizer Composiciones de polinucleotidos y sus usos
TW202340460A (zh) 2021-12-17 2023-10-16 美商旗艦先鋒創新有限責任公司 用於在變性條件下富集環狀ｒｎａ之方法
EP4452239A1 (en) 2021-12-20 2024-10-30 Sail Biomedicines, Inc. Compositions comprising mrna and lipid reconstructed plant messenger packs
KR20240117149A (ko) 2021-12-22 2024-07-31 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 폴리리보뉴클레오티드를 정제하기 위한 조성물 및 방법
CA3243054A1 (en) 2021-12-23 2025-04-08 Renagade Therapeutics Management Inc. Constrained Lipids and Associated Utilization Processes
CA3241492A1 (en) 2021-12-23 2023-06-29 Suzhou Abogen Biosciences Co., Ltd. Lipid compound and lipid nanoparticle composition
EP4452337A1 (en) 2021-12-23 2024-10-30 Flagship Pioneering Innovations VI, LLC Circular polyribonucleotides encoding antifusogenic polypeptides
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
EP4463475A2 (en) 2022-01-14 2024-11-20 Anjarium Biosciences AG Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
EP4467135A1 (en) * 2022-01-17 2024-11-27 ST Pharm Co., Ltd. Ionizable lipid containing biodegradable ester bond and lipid nanoparticles comprising same
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
CA3266086A1 (en) * 2022-01-24 2023-07-27 Verily Life Sciences Llc IONIZABLE LIPIDS, LIPID NANOPARTICLES AND THEIR USES
WO2023144193A1 (en) 2022-01-25 2023-08-03 CureVac SE Mrnas for treatment of hereditary tyrosinemia type i
EP4469063A1 (en) 2022-01-27 2024-12-04 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
CN114409554A (zh) * 2022-01-27 2022-04-29 英维沃生物科技(苏州)有限公司 一种新型阳离子脂质化合物及其组合物和用途
EP4469091A1 (en) 2022-01-28 2024-12-04 CureVac SE Nucleic acid encoded transcription factor inhibitors
EP4475882A1 (en) 2022-02-09 2024-12-18 ModernaTX, Inc. Mucosal administration methods and formulations
US20250381213A1 (en) 2022-02-10 2025-12-18 Christiana Care Gene Editing Institute, Inc. Methods for lipid nanoparticle delivery of crispr/cas system
EP4479085A1 (en) 2022-02-18 2024-12-25 ModernaTX, Inc. Mrnas encoding checkpoint cancer vaccines and uses thereof
KR20240161965A (ko) 2022-03-14 2024-11-13 제너레이션 바이오 컴퍼니 이종 프라임 부스트 백신 조성물 및 사용 방법
WO2023177904A1 (en) 2022-03-18 2023-09-21 Modernatx, Inc. Sterile filtration of lipid nanoparticles and filtration analysis thereof for biological applications
KR20240166554A (ko) 2022-03-25 2024-11-26 세일 바이오메디슨스, 인크. 신규한 이온화 가능 지질 및 지질 나노입자, 및 이를 사용하는 방법
AU2023251104A1 (en) 2022-04-07 2024-10-17 Renagade Therapeutics Management Inc. Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
JP2025511756A (ja) 2022-04-08 2025-04-16 フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー ワクチン及び関連する方法
WO2023201204A1 (en) 2022-04-11 2023-10-19 Modernatx, Inc. Detection of mrna purity in a mixture
CN117396538A (zh) * 2022-04-12 2024-01-12 厦门赛诺邦格生物科技股份有限公司 一种含有叔胺的非线性聚乙二醇化脂质及其应用
WO2023215796A2 (en) * 2022-05-04 2023-11-09 The Trustees Of The University Of Pennsylvania Siloxane-based lipids, lipid nanoparticle compositions comprising the same, and methods of use thereof for targeted delivery
WO2023220083A1 (en) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods of use for treating proliferative disorders
WO2023218420A1 (en) 2022-05-13 2023-11-16 Janssen Pharmaceuticals, Inc. Mrna compositions for inducing latent hiv-1 reversal
EP4522753A2 (en) 2022-05-13 2025-03-19 Flagship Pioneering Innovations VII, LLC Double stranded dna compositions and related methods
WO2023218431A1 (en) 2022-05-13 2023-11-16 BioNTech SE Rna compositions targeting hiv
US20250340586A1 (en) 2022-05-17 2025-11-06 Modernatx, Inc. Preparation of highly concentrated mrna
WO2023230295A1 (en) 2022-05-25 2023-11-30 BioNTech SE Rna compositions for delivery of monkeypox antigens and related methods
US20250345407A1 (en) 2022-05-25 2025-11-13 CureVac SE Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
CN119562807A (zh) 2022-05-30 2025-03-04 生物技术公司 用于递送核酸的复合物
JP2025520127A (ja) 2022-06-02 2025-07-01 スクライブ・セラピューティクス・インコーポレイテッド 操作されたクラス２タイプｖ ｃｒｉｓｐｒ系
EP4536819A1 (en) 2022-06-07 2025-04-16 Scribe Therapeutics Inc. Compositions and methods for the targeting of pcsk9
CA3257914A1 (en) 2022-06-07 2023-12-14 Scribe Therapeutics Inc. COMPOSITIONS AND METHODS FOR TARGETING PCSK9
CA3258303A1 (en) 2022-06-07 2023-12-14 Generation Bio Co. Compositions of lipid nanoparticles and their uses
EP4539876A2 (en) 2022-06-18 2025-04-23 GlaxoSmithKline Biologicals S.A. Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
US20250179492A1 (en) 2022-06-22 2025-06-05 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
WO2023248128A1 (en) 2022-06-23 2023-12-28 Pfizer Inc. Use of a spray freeze-drying process for the lyophilization of a mrna-encapsulating lipid nanoparticles formulation
KR20250044484A (ko) 2022-06-24 2025-03-31 튠 쎄라퓨틱스, 인코포레이티드 표적 유전자 억제를 통해 저밀도 지단백질을 감소시키기 위한 조성물, 시스템, 및 방법
WO2023250119A1 (en) 2022-06-24 2023-12-28 Modernatx, Inc. Methods of producing rna
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN120051297A (zh) 2022-06-30 2025-05-27 因达普塔治疗公司 工程化自然杀伤(nk)细胞与抗体疗法的组合及相关方法
CN119855910A (zh) 2022-07-06 2025-04-18 美国微哲默理有限责任公司 用于治疗胰腺癌的组合物和方法
EP4551247A1 (en) 2022-07-07 2025-05-14 The United States of America, as represented by the Secretary, Department of Health and Human Services Immunogens and methods for inducing an immune response
WO2024015881A2 (en) 2022-07-12 2024-01-18 Tune Therapeutics, Inc. Compositions, systems, and methods for targeted transcriptional activation
TW202413424A (zh) 2022-08-01 2024-04-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 免疫調節蛋白及相關方法
CN117126071A (zh) * 2022-08-12 2023-11-28 上海蓝鹊生物医药有限公司 含氮链状化合物、其制备方法、包含其的组合物和应用
EP4569112A1 (en) 2022-08-12 2025-06-18 Remix Therapeutics Inc. Methods and compositions for modulating splicing at alternative splice sites
JP2025527583A (ja) 2022-08-18 2025-08-22 スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド 脂質ナノ粒子の組成物
CN120435557A (zh) 2022-08-19 2025-08-05 图恩疗法股份有限公司 通过靶向基因阻遏调节乙型肝炎病毒的组合物、系统和方法
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof
WO2024044147A1 (en) 2022-08-23 2024-02-29 Modernatx, Inc. Methods for purification of ionizable lipids
AU2023329397A1 (en) * 2022-08-26 2025-03-06 Renagade Therapeutics Management Inc. Pegylated lipid compounds and methods of use thereof
WO2024049979A2 (en) 2022-08-31 2024-03-07 Senda Biosciences, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
EP4587166A1 (en) 2022-09-15 2025-07-23 Pfizer Inc. Coaxial flow device for nanoparticle preparation and manufacturing equipment including such device
WO2024057237A1 (en) 2022-09-16 2024-03-21 Pfizer Inc. Lipid nanoparticles
KR20250073120A (ko) 2022-09-19 2025-05-27 쑤저우 선카디아 바이오파마수티컬즈 컴퍼니 리미티드 2-히드록시에틸 아미노카프로에이트계 화합물을 제조하는 방법 및 이의 용도
EP4590821A2 (en) 2022-09-19 2025-07-30 Tune Therapeutics, Inc. Compositions, systems, and methods for modulating t cell function
WO2024063788A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
IL319414A (en) 2022-09-23 2025-05-01 BioNTech SE Compositions for delivering antigens at the liver level and related methods
WO2024063789A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
AU2023347390A1 (en) 2022-09-23 2025-04-10 BioNTech SE Compositions for delivery of plasmodium csp antigens and related methods
AU2023353931A1 (en) 2022-09-26 2025-03-20 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024074211A1 (en) 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2
AU2023357320A1 (en) 2022-10-06 2025-04-17 BioNTech SE Rna compositions targeting claudin-18.2
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
TWI888970B (zh) 2022-10-27 2025-07-01 美商輝瑞大藥廠 Rna分子
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
WO2024091037A1 (ko) * 2022-10-27 2024-05-02 에스티팜 주식회사 폐를 표적장기로 하는 생분해성 지질나노입자 약물 전달 제형 및 이의 활용
WO2024089229A1 (en) 2022-10-28 2024-05-02 CureVac SE Improved formulations comprising lipid-based carriers encapsulating rna
US12186389B2 (en) 2022-10-28 2025-01-07 Glaxosmithkline Biologicals Sa Nucleic acid base vaccine against emerging SARS-CoV-2 variants
KR20250099195A (ko) 2022-10-31 2025-07-01 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 폴리리보뉴클레오티드를 정제하기 위한 조성물 및 방법
CN120035576B (zh) * 2022-11-03 2025-12-12 上海环码生物医药有限公司 脂质化合物、脂质纳米颗粒和药物组合物
US20250367129A1 (en) 2022-11-04 2025-12-04 Pfizer Inc. Lipid Compounds and Uses Thereof
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
JP2025535566A (ja) * 2022-11-08 2025-10-24 サムヤン ホールディングス コーポレイション カチオン性脂質及びその製造方法
AR131008A1 (es) 2022-11-08 2025-02-05 Flagship Pioneering Innovations Vi Llc Composiciones y métodos para producir polirribonucleótidos circulares
WO2024102730A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and nanoparticle compositions for delivering polynucleotides
AU2023375897A1 (en) 2022-11-08 2025-06-12 Orna Therapeutics, Inc. Circular rna compositions
JP2025537750A (ja) 2022-11-10 2025-11-20 セイル バイオメディシンズ インコーポレイテッド 脂質ナノ粒子または脂質再構成天然メッセンジャーパックを含むｒｎａ組成物
CN120265279A (zh) 2022-11-21 2025-07-04 翻译生物公司 信使rna的干粉配制品的组合物及其使用方法
KR20250129819A (ko) 2022-12-01 2025-08-29 제너레이션 바이오 컴퍼니 핵산, 이온화 가능한 지질, 스테롤, 지질에 고정된 중합체, 및 헬퍼 지질을 포함하는 지질 나노입자 및 이의 용도
WO2024119051A1 (en) 2022-12-01 2024-06-06 Generation Bio Co. Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
EP4626402A1 (en) 2022-12-01 2025-10-08 Generation Bio Co. Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
JP2025541726A (ja) 2022-12-01 2025-12-23 ジェネレーション バイオ カンパニー 細胞標的化のためのステルス脂質ナノ粒子組成物
WO2024123633A1 (en) 2022-12-08 2024-06-13 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
EP4630561A1 (en) 2022-12-09 2025-10-15 Takeda Pharmaceutical Company Limited Modified immunomodulators
WO2024127181A1 (en) 2022-12-11 2024-06-20 Pfizer Inc. Immunogenic compositions against influenza and rsv
CN115819265A (zh) * 2022-12-13 2023-03-21 广东和境生物科技有限公司 一种含酰胺键脂质的合成方法
TW202430215A (zh) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 用於將治療劑遞送至骨之組成物和方法
EP4633673A1 (en) 2022-12-15 2025-10-22 Sanofi Pasteur Inc. Mrna encoding influenza virus-like particle
CN116284743A (zh) * 2022-12-16 2023-06-23 辅必成（上海）医药科技有限公司 一种甲氧基聚乙二醇2000双十四烷基乙酰胺的制备方法
EP4637812A1 (en) 2022-12-19 2025-10-29 GlaxoSmithKline Biologicals S.A. Hepatitis b compositions
TW202438514A (zh) 2022-12-20 2024-10-01 法商賽諾菲公司 鼻病毒mrna疫苗
WO2024134551A1 (en) 2022-12-23 2024-06-27 Pfizer Inc. Lipid particle compositions and methods of use thereof
CN121127490A (zh) 2022-12-28 2025-12-12 生物技术欧洲股份公司 靶向hiv的rna组合物
WO2024141786A2 (en) 2022-12-29 2024-07-04 Popvax Private Limited Multitarget vaccines and therapeutics
WO2024141784A2 (en) 2022-12-29 2024-07-04 Popvax Private Limited Broadly protective betacoronavirus vaccines and compositions
CN115677518B (zh) * 2023-01-05 2023-04-14 北京悦康科创医药科技股份有限公司 用于递送核酸的可电离阳离子脂质化合物和组合物及用途
US20240252520A1 (en) 2023-01-09 2024-08-01 Beth Israel Deaconess Medical Center, Inc. Therapeutic agents and their use for treating chronic wounds
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024151673A2 (en) 2023-01-09 2024-07-18 President And Fellows Of Harvard College Recombinant nucleic acid molecules and their use in wound healing
TW202438673A (zh) 2023-01-09 2024-10-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 疫苗及相關方法
EP4648793A1 (en) 2023-01-11 2025-11-19 ModernaTX, Inc. Personalized cancer vaccines
WO2024154052A1 (en) 2023-01-16 2024-07-25 Pfizer Inc. Immunogenic compositions and methods of inducing an immune response against varicella zoster virus
AU2024212425A1 (en) 2023-01-27 2025-08-07 Sail Biomedicines, Inc. A modified lipid composition and uses thereof
EP4658636A1 (en) 2023-01-31 2025-12-10 Pfizer Inc. Lipid compounds and uses thereof
WO2024163683A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
WO2024163678A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
EP4658239A1 (en) 2023-02-03 2025-12-10 GlaxoSmithKline Biologicals S.A. Rna formulation
WO2024167885A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods
IL322468A (en) 2023-02-13 2025-09-01 Flagship Pioneering Innovations Vii Llc Ionizable lipids containing degradable crosslinkers and lipid carriers for therapeutic compositions
GB202302092D0 (en) 2023-02-14 2023-03-29 Glaxosmithkline Biologicals Sa Analytical method
AU2024220221A1 (en) 2023-02-17 2025-08-07 Flagship Pioneering Innovations Vii, Llc Dna compositions comprising modified cytosine
EP4665405A1 (en) 2023-02-17 2025-12-24 Flagship Pioneering Innovations VII, LLC Dna compositions comprising modified uracil
DE112024001143T5 (de) 2023-03-08 2025-12-18 CureVac SE Neue lipid-nanopartikel-formeln für die abgabe von nukleinsäuren
KR20250162610A (ko) 2023-03-15 2025-11-18 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 폴리리보뉴클레오티드를 포함하는 조성물 및 이의 용도
WO2024192422A1 (en) 2023-03-15 2024-09-19 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
CN118666726A (zh) * 2023-03-17 2024-09-20 尧唐(上海)生物科技有限公司 递送治疗剂的脂质化合物及其制备方法与应用
TW202444921A (zh) 2023-03-29 2024-11-16 美商斯奎柏治療公司 用於靶向lpa之組合物及方法
TW202444914A (zh) 2023-03-29 2024-11-16 美商斯奎柏治療公司 抑制子融合蛋白系統
WO2024205657A2 (en) 2023-03-29 2024-10-03 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
TW202444906A (zh) 2023-03-29 2024-11-16 美商斯奎柏治療公司 用於靶向pcsk9之組合物及方法
WO2024206835A1 (en) 2023-03-30 2024-10-03 Modernatx, Inc. Circular mrna and production thereof
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
WO2024200823A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
TW202449142A (zh) 2023-04-07 2024-12-16 日商武田藥品工業股份有限公司 接合複合物
CN120813424A (zh) 2023-04-07 2025-10-17 阿斯利康(瑞典)有限公司 用于纳米颗粒产生的流体混合器单元装置
AU2024255972A1 (en) 2023-04-12 2025-10-23 Flagship Pioneering Innovations Vi, Llc Modified trems, compositions, and related methods thereof
AU2024252590A1 (en) 2023-04-12 2025-10-23 Flagship Pioneering Innovations Vi, Llc Trems for use in correction of missense mutations
KR20250169625A (ko) 2023-04-17 2025-12-03 사노피 파스퇴르 인크 재구성 가능한 건조 분말 제형 및 이의 사용 방법
WO2024220752A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Rna therapeutic compositions
WO2024220625A1 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids
WO2024220712A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Vaccine compositions
WO2024220746A2 (en) 2023-04-21 2024-10-24 Flagship Pioneering Innovations Vii, Llc Rnai agents targeting fatty acid synthase and related methods
WO2024223724A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024223728A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024228044A1 (en) 2023-05-03 2024-11-07 BioNTech SE Optimized csp variants and related methods
WO2024229309A2 (en) 2023-05-03 2024-11-07 Manifold Biotechnologies, Inc. Methodsand compositions for high-throughput protein delivery, screening, and detection
CN121038807A (zh) 2023-05-03 2025-11-28 生物技术欧洲股份公司 优化的csp变体及相关方法
US20240417370A1 (en) 2023-05-05 2024-12-19 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2024233308A2 (en) 2023-05-05 2024-11-14 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
WO2024238700A1 (en) 2023-05-15 2024-11-21 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
WO2024236361A1 (en) 2023-05-15 2024-11-21 Takeda Pharmaceutical Company Limited Compositions and methods for delivery of nucleic acids to cells
AU2024270764A1 (en) 2023-05-15 2025-12-04 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
WO2024236504A1 (en) 2023-05-15 2024-11-21 Takeda Pharmaceutical Company Limited Sequences and methods for delivery of dna and rna
CN116270543B (zh) * 2023-05-19 2023-09-26 清华大学 脂质纳米颗粒在制备通过雾吸或鼻滴给药递送核酸的药物中的用途
WO2024243438A2 (en) 2023-05-23 2024-11-28 Omega Therapeutics, Inc. Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
WO2024258829A1 (en) 2023-06-12 2024-12-19 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2024256962A1 (en) 2023-06-14 2024-12-19 Pfizer Inc. Method for stabilizing rna
CN119143620A (zh) * 2023-06-16 2024-12-17 北京剂泰医药科技有限公司 一种快速代谢的脂质化合物
US20240423914A1 (en) 2023-06-16 2024-12-26 Acuitas Therapeutics, Inc. Amide containing lipids
US20240423915A1 (en) 2023-06-16 2024-12-26 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticles
US20250025427A1 (en) 2023-06-16 2025-01-23 Acuitas Therapeutics, Inc. Mixed amide ester containing lipids for use in lipid nanoparticles
WO2024260570A1 (en) 2023-06-23 2024-12-26 CureVac SE Nucleic acid encoded antibodies
WO2025006684A1 (en) 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
US20250001010A1 (en) 2023-06-30 2025-01-02 Christiana Care Gene Editing Institute, Inc. Nras gene knockout for treatment of cancer
WO2025006385A1 (en) 2023-06-30 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Novel malaria vaccine comprising ama1 and ron2 antigens
US20250025428A1 (en) * 2023-07-06 2025-01-23 SunVax mRNA Therapeutics Inc. Compositions and methods for delivering molecules
WO2025011529A2 (en) 2023-07-07 2025-01-16 Shanghai Circode Biomed Co., Ltd. Circular rna vaccines for seasonal flu and methods of uses
WO2025017476A1 (en) 2023-07-19 2025-01-23 Pfizer Inc. Lipid nanoparticles comprising polymer-conjugated lipids and uses thereof
WO2025024335A2 (en) 2023-07-21 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
WO2025024324A1 (en) 2023-07-21 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
WO2025024337A1 (en) 2023-07-24 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
TW202516001A (zh) 2023-07-25 2025-04-16 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 Ｃａｓ內切酶及相關方法
WO2025027492A1 (en) 2023-07-31 2025-02-06 Pfizer Inc. Coronavirus antigen variants
WO2025029835A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for modulating il-2 gene expression
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
WO2025026545A1 (en) 2023-08-01 2025-02-06 BioNTech SE Ionizable thioplipids and uses thereof
WO2025027116A1 (en) 2023-08-01 2025-02-06 Institut Curie Nanoparticles comprising nucleic acid sequences encoding cyclic gmp-amp synthase
TW202519509A (zh) 2023-08-01 2025-05-16 德商拜恩技術股份公司 可離子化硫脂質及其用途
WO2025030154A1 (en) 2023-08-03 2025-02-06 The Trustees Of The University Of Pennsylvania Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
WO2025027576A2 (en) 2023-08-03 2025-02-06 BioNTech SE Rna compositions targeting hiv
WO2025030097A2 (en) 2023-08-03 2025-02-06 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
WO2025027579A2 (en) 2023-08-03 2025-02-06 BioNTech SE Rna compositions targeting hiv
WO2025038494A1 (en) 2023-08-11 2025-02-20 Tune Therapeutics, Inc. Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
WO2025036992A1 (en) 2023-08-16 2025-02-20 CureVac SE Rna conjugates
WO2025042786A1 (en) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
WO2025049690A1 (en) 2023-08-29 2025-03-06 Orna Therapeutics, Inc. Circular polyethylene glycol lipids
WO2025045142A1 (en) 2023-08-29 2025-03-06 Shanghai Circode Biomed Co., Ltd. Circular rna encoding vegf polypeptides, formulations, and methods of uses
WO2025054236A2 (en) 2023-09-06 2025-03-13 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025051994A1 (en) 2023-09-07 2025-03-13 Coave Therapeutics Ionizable lipid nanoparticles
WO2025052180A2 (en) 2023-09-07 2025-03-13 Axelyf ehf. Lipids and lipid nanoparticles
WO2025054556A1 (en) 2023-09-07 2025-03-13 BioNTech SE Rna compositions for delivery of mpox antigens and related methods
WO2025057088A1 (en) 2023-09-11 2025-03-20 BioNTech SE Rna compositions for delivery of incretin agents
WO2025059073A1 (en) 2023-09-11 2025-03-20 Tune Therapeutics, Inc. Epigenetic editing methods and systems for differentiating stem cells
WO2025057115A2 (en) 2023-09-15 2025-03-20 Pfizer Inc. Methods and compositions for continuous production of nucleic acids
TW202525266A (zh) 2023-09-18 2025-07-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 可電離類脂質組成物及其治療用途
WO2025064850A1 (en) 2023-09-22 2025-03-27 BioNTech SE Rna constructs with n-terminal degrons to enhance an immune response
WO2025072331A1 (en) 2023-09-26 2025-04-03 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
KR20250060128A (ko) * 2023-10-24 2025-05-07 주식회사 삼양홀딩스 약물전달용 나노입자의 조성물
WO2025088088A1 (en) 2023-10-27 2025-05-01 CureVac SE Rna composition for improving cell therapy
WO2025096807A2 (en) 2023-10-31 2025-05-08 Flagship Pioneering Innovations Vii, Llc Novel therapeutic dna forms
KR20250064439A (ko) * 2023-11-02 2025-05-09 주식회사 삼양홀딩스 양이온성 지질 및 이의 제조방법
WO2025101501A1 (en) 2023-11-07 2025-05-15 Orna Therapeutics, Inc. Circular rna compositions
WO2025103803A1 (en) 2023-11-13 2025-05-22 CureVac SE Immunotherapy against neuronal and brain tumors
TW202535835A (zh) 2023-11-14 2025-09-16 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 可電離類脂質組成物及其治療用途
WO2025106754A1 (en) 2023-11-15 2025-05-22 BioNTech SE Coronavirus vaccine
KR20250071877A (ko) 2023-11-15 2025-05-22 바이오엔테크 에스이 Sars-cov-2 면역원성 조성물
WO2025106915A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof
WO2025106930A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 2 (glp-2) and uses thereof
US20250161227A1 (en) 2023-11-17 2025-05-22 Acuitas Therapeutics, Inc. Pegylated lipids
US20250161347A1 (en) 2023-11-22 2025-05-22 Flagship Pioneering Innovations Vii, Llc Methods and compositions for treating non-alcoholic fatty liver disease
WO2025117877A2 (en) 2023-12-01 2025-06-05 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
US12364773B2 (en) 2023-12-01 2025-07-22 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
WO2025114520A1 (en) 2023-12-01 2025-06-05 Coave Therapeutics Ionizable lipid nanoparticles
US20250188016A1 (en) 2023-12-12 2025-06-12 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
WO2025126019A1 (en) 2023-12-13 2025-06-19 Pfizer Inc. Rna molecules
WO2025124711A1 (en) 2023-12-13 2025-06-19 BioNTech SE Glycolipid compositions
TW202532053A (zh) * 2023-12-13 2025-08-16 大陸商上海瑞宏迪醫藥有限公司 用於遞送治療劑的組成物和化合物
WO2025132122A1 (en) 2023-12-13 2025-06-26 Berlin Institute Of Health Methods of delivering therapeutics using lipid nanoparticles
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025129128A1 (en) 2023-12-15 2025-06-19 Vivasor, Inc. Compositions and methods for non-viral delivery of therapeutic compounds
WO2025126113A1 (en) 2023-12-15 2025-06-19 Pfizer Inc. Lipid compounds and uses thereof
WO2025126118A1 (en) 2023-12-15 2025-06-19 Pfizer Inc. Lipid compounds and uses thereof
WO2025133105A1 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Compositions and methods
WO2025134066A1 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Ionizable lipids
WO2025134062A2 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Ionizable lipids
WO2025132839A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2025133115A1 (en) 2023-12-21 2025-06-26 Ose Immunotherapeutics Lipid-based nanoparticles comprising il-35
WO2025134046A1 (en) 2023-12-22 2025-06-26 Pfizer Inc. Methods and vaccine compositions for lyme disease
WO2025137646A1 (en) 2023-12-22 2025-06-26 Recode Therapeutics, Inc. Gene editing methods and compositions for treating cystic fibrosis
WO2025144938A1 (en) 2023-12-26 2025-07-03 Emmune, Inc. Systems for nucleic acid transfer
WO2025149492A1 (en) 2024-01-08 2025-07-17 BioNTech SE Rna encoding an immune inhibitory il-1 family member
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
US20250375499A1 (en) 2024-01-26 2025-12-11 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025166325A1 (en) 2024-02-02 2025-08-07 Editas Medicine, Inc. MODIFIED GUIDE RNAs
WO2025166993A1 (zh) * 2024-02-05 2025-08-14 复旦大学 一种新型脂质化合物以及组合物和核酸脂质纳米颗粒制剂及其筛选方法和应用
WO2025171182A1 (en) 2024-02-08 2025-08-14 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
WO2025174858A1 (en) 2024-02-15 2025-08-21 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
WO2025184508A1 (en) 2024-03-01 2025-09-04 Acuitas Therapeutics, Inc. Materials and methods for encapsulating therapeutics in lipid nanoparticles
WO2025186719A1 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions and uses thereof
WO2025186725A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Improved lnp formulations and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025194138A1 (en) 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. St1cas9 compositions and methods for modulating a genome
WO2025194019A1 (en) 2024-03-14 2025-09-18 Flagship Pioneering Innovations Vii, Llc Methods for treating liver fibrosis and non-alcoholic fatty liver disease
WO2025192731A1 (ja) * 2024-03-15 2025-09-18 富士フイルム株式会社 化合物またはその塩、脂質組成物、医薬組成物および送達キャリア
WO2025196065A1 (en) 2024-03-20 2025-09-25 Sanofi Novel homocysteine based lipids and their use for delivery of nucleic acids
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines
WO2025202834A1 (en) 2024-03-26 2025-10-02 Pfizer Inc. Polynucleotide compositions and uses thereof
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation
WO2025213016A2 (en) 2024-04-04 2025-10-09 Christiana Care Gene Editing Institute, Inc. Crispr/cas gene editing of neh4 and/or neh5 domains in nrf2
WO2025213131A1 (en) 2024-04-05 2025-10-09 BioNTech SE Rna compositions for delivery of orthopox antigens and related methods
WO2025213138A1 (en) 2024-04-05 2025-10-09 Editas Medicine, Inc. Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
WO2025217275A2 (en) 2024-04-10 2025-10-16 Flagship Pioneering Innovations Vii, Llc Immune cell targeted compositions and related methods
WO2025217264A1 (en) 2024-04-10 2025-10-16 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
WO2025226816A1 (en) 2024-04-23 2025-10-30 Christiana Care Gene Editing Institute, Inc. Methods of identifying and correlating crispr-induced exon skipping to phenotypic outcomes
WO2025231114A1 (en) 2024-05-01 2025-11-06 Acuitas Therapeutics, Inc. Method of using lipid nanoparticles for intramuscular delivery
WO2025229572A1 (en) 2024-05-01 2025-11-06 Glaxosmithkline Biologicals Sa Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines
WO2025240680A1 (en) 2024-05-16 2025-11-20 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025240940A1 (en) 2024-05-17 2025-11-20 Scribe Therapeutics Inc. Compositions and methods for the targeting of apolipoprotein c3
WO2025240833A1 (en) 2024-05-17 2025-11-20 Acuitas Therapeutics, Inc. Galnac lipid compounds for use in lipid nanoparticles
WO2025238563A1 (en) 2024-05-17 2025-11-20 Pfizer Inc. Coaxial mixing device for nanoparticle preparation and manufacturing equipment including such mixing device
WO2025245188A2 (en) 2024-05-21 2025-11-27 Flagship Pioneering Innovations Vii, Llc Methods of treating liver steatosis and non-alcoholic fatty liver disease
WO2025245111A1 (en) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Immunoreceptor targeting proteins and related methods
WO2025242815A1 (en) 2024-05-23 2025-11-27 CureVac SE Immunotherapy of squamous cell carcinoma

Family Cites Families (241)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2856420A (en) * 1955-12-15 1958-10-14 Minnesota Mining & Mfg Perfluoro- and perfluorochlorocarboxylic acid esters of amino alcohols
US3340299A (en) 1964-03-27 1967-09-05 Air Reduction Tetrasubstituted ethylene diamines
GB1277947A (en) 1968-08-22 1972-06-14 Armour Ind Chem Co Compositions and method for controlling insect pests
US3729564A (en) 1970-12-16 1973-04-24 Pfizer N-secondary alkyl alkanediamines and derivatives thereof as anti-inflammatory agents
JPS5122416B2 (OSRAM) * 1972-11-11 1976-07-09
DE2633615C3 (de) 1976-07-27 1981-08-13 Bayer Ag, 5090 Leverkusen Verfahren zum Färben von synthetischen Polyamid-Fasermaterialien
DE3010599A1 (de) 1979-03-22 1980-10-09 Continental Pharma Derivate von glycinamid, deren herstellung und verwendung
JPS56150002A (en) * 1980-04-23 1981-11-20 Nisshin Flour Milling Co Ltd Nonaprenylamine derivative
US4883751A (en) 1986-05-28 1989-11-28 New York University Specific immunoassay for heparin
US6036957A (en) 1990-03-30 2000-03-14 Autoimmune, Inc. Suppression of T-cell proliferation using peptide fragments of myelin basic protein
JP2651742B2 (ja) * 1990-05-28 1997-09-10 富士写真フイルム株式会社 色素固定要素
JP2588339B2 (ja) 1992-06-02 1997-03-05 花王株式会社 新規ジアミノジエステル及びその製造法
US6197553B1 (en) 1994-07-15 2001-03-06 Merck & Co., Inc. Method for large scale plasmid purification
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
AU723163B2 (en) 1995-06-07 2000-08-17 Tekmira Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
JPH11510489A (ja) 1995-07-21 1999-09-14 ジンタ・インコーポレイテッド 新規アミド基本カチオン性脂質
DE19605175A1 (de) 1996-02-13 1997-08-14 Sourovoi Andrej Dr Lipidverbindungen und deren Verwendung
JPH103643A (ja) 1996-06-12 1998-01-06 Fuji Photo Film Co Ltd ディスク状磁気記録媒体
EP0948587B1 (en) 1996-10-11 2003-05-07 Infineum Holdings BV Fuel compositions
CA2217550A1 (en) 1996-10-22 1998-04-22 F. Hoffmann-La Roche Ag Cationic lipids for gene therapy
US6884430B1 (en) 1997-02-10 2005-04-26 Aventis Pharma S.A. Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
US5965542A (en) 1997-03-18 1999-10-12 Inex Pharmaceuticals Corp. Use of temperature to control the size of cationic liposome/plasmid DNA complexes
US5756785A (en) 1997-03-21 1998-05-26 Lambent Technologies, Inc. Guerbet betaines
FR2763943B1 (fr) 1997-05-28 1999-07-09 Rhone Poulenc Rorer Sa Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
US20030073640A1 (en) 1997-07-23 2003-04-17 Ribozyme Pharmaceuticals, Inc. Novel compositions for the delivery of negatively charged molecules
EP1041976B1 (en) 1997-12-23 2006-04-05 Inex Pharmaceuticals Corp. Polyamide oligomers
US6410328B1 (en) 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
US6986902B1 (en) 1998-04-28 2006-01-17 Inex Pharmaceuticals Corporation Polyanionic polymers which enhance fusogenicity
US6013813A (en) 1998-06-17 2000-01-11 Hansotech Inc Guerbet based sorbitan esters
US6333433B1 (en) 1998-11-09 2001-12-25 Council Of Scientific Industrial Research Process for synthesis of novel cationic amphiphiles containing N-hydroxyalkl group for intracellular delivery of biologically active molecules
WO2000030444A1 (en) 1998-11-25 2000-06-02 Vanderbilt University Cationic liposomes for gene transfer
US5919743A (en) 1998-12-28 1999-07-06 Petroferm Inc. Guerbet branched quaternary compounds in personal care applications
US7112337B2 (en) 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
US6211140B1 (en) 1999-07-26 2001-04-03 The Procter & Gamble Company Cationic charge boosting systems
DE69943068D1 (de) 1999-09-09 2011-02-03 Curevac Gmbh Transfer von mRNA unter Verwendung von polykationischen Verbindungen
GB9930533D0 (en) 1999-12-23 2000-02-16 Mitsubishi Tokyo Pharm Inc Nucleic acid delivery
JP2001338416A (ja) 2000-05-25 2001-12-07 Sony Corp ディスク状磁気記録媒体
US20040142474A1 (en) 2000-09-14 2004-07-22 Expression Genetics, Inc. Novel cationic lipopolymer as a biocompatible gene delivery agent
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
JP4111856B2 (ja) 2002-04-12 2008-07-02 昭和電工株式会社 安定化されたアスコルビン酸誘導体
US7419817B2 (en) 2002-05-17 2008-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
EP2338478B1 (en) 2002-06-28 2014-07-23 Protiva Biotherapeutics Inc. Method for producing liposomes
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
US6620794B1 (en) 2002-07-08 2003-09-16 Colonial Chemical Inc. Guerbet functionalized phospholipids
JP4951338B2 (ja) 2003-07-16 2012-06-13 プロチバ バイオセラピューティクス インコーポレイティッド 脂質に封入された干渉ｒｎａ
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
JP4842821B2 (ja) 2003-09-15 2011-12-21 プロチバ バイオセラピューティクス インコーポレイティッド ポリエチレングリコール修飾脂質化合物およびその使用
AU2005251691A1 (en) 2004-05-17 2005-12-22 Tekmira Pharmaceuticals Corporation Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
AU2005252273B2 (en) 2004-06-07 2011-04-28 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
US8192718B1 (en) 2005-01-04 2012-06-05 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8141043B2 (en) 2005-01-11 2012-03-20 Worksoft, Inc. Automated business process testing that spans multiple platforms or applications
WO2007086881A2 (en) 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
EP2476756A1 (en) 2005-06-15 2012-07-18 Massachusetts Institute of Technology Amine-containing lipids and uses thereof
EP1937213B1 (en) 2005-07-27 2017-10-25 Protiva Biotherapeutics Inc. Systems and methods for manufacturing liposomes
EP4174179B1 (en) 2005-08-23 2025-05-07 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
US7443760B2 (en) 2005-09-29 2008-10-28 Hynix Semiconductor Inc. Multi-port memory device with serial input/output interface
JP4681425B2 (ja) 2005-11-15 2011-05-11 花王株式会社 毛髪弾性改善剤
GB2433928B (en) 2006-01-07 2009-10-14 Shane Richard Wootton Apparatus for producing material by a chemical reaction
DE102006035618A1 (de) 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
CN105030654A (zh) 2006-10-03 2015-11-11 阿尔尼拉姆医药品有限公司 含脂质的制品
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
AU2008219165A1 (en) 2007-02-16 2008-08-28 Merck Sharp & Dohme Corp. Compositions and methods for potentiated activity of biologicaly active molecules
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
CA2891005A1 (en) 2007-09-28 2008-10-09 Bind Therapeutics, Inc. Cancer cell targeting using nanoparticles
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
CA2910760C (en) 2007-12-04 2019-07-09 Muthiah Manoharan Targeting lipids
AU2008347250A1 (en) 2008-01-02 2009-07-16 Tekmira Pharmaceuticals Corporation Screening method for selected amino lipid-containing compositions
US20110045473A1 (en) 2008-01-02 2011-02-24 De Fougerolles Antonin Liver screening method
EP3100718B1 (en) 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
HRP20150528T2 (hr) 2008-01-31 2016-03-25 Curevac Gmbh NUKLEINSKE KISELINE KOJE SADRŽE FORMULU (NuGiXmGnNv)a TE NJIHOVI DERIVATI KAO IMUNOSTIMULACIJSKA SREDSTVA/POMOĆNA SREDSTVA
US9446995B2 (en) * 2012-05-21 2016-09-20 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
WO2009126933A2 (en) 2008-04-11 2009-10-15 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
JP5475753B2 (ja) 2008-04-15 2014-04-16 プロチバ バイオセラピューティクス インコーポレイティッド 核酸送達用の脂質製剤
US20090263407A1 (en) 2008-04-16 2009-10-22 Abbott Laboratories Cationic Lipids and Uses Thereof
US20090285881A1 (en) 2008-04-16 2009-11-19 Abbott Laboratories Cationic lipids and uses thereof
WO2009132131A1 (en) 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Amino lipid based improved lipid formulation
EP2309991B1 (en) 2008-06-16 2019-03-06 Pfizer Inc Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
EP2285350B1 (en) 2008-06-16 2017-11-15 Pfizer Inc Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic nanoparticles
EP2309990B2 (en) 2008-06-16 2017-03-15 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
WO2010021865A1 (en) 2008-08-18 2010-02-25 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
US20100087337A1 (en) 2008-09-10 2010-04-08 Bind Biosciences, Inc. High Throughput Fabrication of Nanoparticles
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
EP3225621A1 (en) * 2008-10-09 2017-10-04 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010048536A2 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Processes for preparing lipids
US20120009222A1 (en) 2008-10-27 2012-01-12 Massachusetts Institute Of Technology Modulation of the immune response
US8722082B2 (en) 2008-11-10 2014-05-13 Tekmira Pharmaceuticals Corporation Lipids and compositions for the delivery of therapeutics
MX338780B (es) 2008-11-10 2016-05-02 Alnylam Pharmaceuticals Inc Lipidos y composiciones novedosas para el suministro de terapeuticos.
CA2742838A1 (en) 2008-11-17 2010-05-20 Enzon Pharmaceuticals, Inc. Releasable polymeric lipids for nucleic acids delivery systems
WO2010080724A1 (en) 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
EP3097908A1 (en) 2009-05-05 2016-11-30 Arbutus Biopharma Corporation Lipid compositions
CA2760706C (en) 2009-05-05 2019-08-06 Alnylam Pharmaceuticals, Inc. Methods of delivering oligonucleotides to immune cells
PL2440183T3 (pl) 2009-06-10 2019-01-31 Arbutus Biopharma Corporation Ulepszona formulacja lipidowa
US9051567B2 (en) 2009-06-15 2015-06-09 Tekmira Pharmaceuticals Corporation Methods for increasing efficacy of lipid formulated siRNA
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
CA2767127A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
WO2011005799A2 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
EP3072881A1 (en) 2009-08-20 2016-09-28 Sirna Therapeutics, Inc. Novel cationic lipids with various head groups for oligonucleotide delivery
US20120264810A1 (en) 2009-09-22 2012-10-18 The University Of British Columbia Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles
EP2485770A4 (en) 2009-10-08 2013-04-10 Merck Sharp & Dohme Novel cationic lipids with short lipid chains for oligonucleotide delivery
EP2496700B1 (en) 2009-11-04 2017-03-01 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
WO2011066651A1 (en) 2009-12-01 2011-06-09 Protiva Biotherapeutics, Inc. Snalp formulations containing antioxidants
EP3296398A1 (en) 2009-12-07 2018-03-21 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
JP5898627B2 (ja) 2009-12-15 2016-04-06 バインド セラピューティックス インコーポレイテッド エポチロンを含む治療用ポリマーナノ粒子ならびにそれを製造および使用する方法
WO2011084513A2 (en) 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
EP3494963A1 (en) 2009-12-18 2019-06-12 The University of British Columbia Methods and compositions for delivery of nucleic acids
WO2011076807A2 (en) * 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
EP2526113B1 (en) 2010-01-22 2016-08-10 Sirna Therapeutics, Inc. Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
US9149432B2 (en) 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
EP2558074B1 (en) 2010-04-08 2018-06-06 The Trustees of Princeton University Preparation of lipid nanoparticles
US20110262491A1 (en) 2010-04-12 2011-10-27 Selecta Biosciences, Inc. Emulsions and methods of making nanocarriers
EP2567952A4 (en) 2010-04-28 2015-11-25 Kyowa Hakko Kirin Co Ltd CATIONIC LIPID
US9408914B2 (en) 2010-04-28 2016-08-09 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
WO2011143230A1 (en) 2010-05-10 2011-11-17 Alnylam Pharmaceuticals Methods and compositions for delivery of active agents
EP2569276B1 (en) 2010-05-12 2021-02-24 Arbutus Biopharma Corporation Novel cationic lipids and methods of use thereof
WO2011141703A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics Inc. Compositions and methods for silencing apolipoprotein b
JP2013531634A (ja) 2010-05-24 2013-08-08 メルク・シャープ・エンド・ドーム・コーポレイション オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質
EP4481047A3 (en) * 2010-06-03 2025-04-16 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US8748667B2 (en) 2010-06-04 2014-06-10 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
AU2011276236B2 (en) 2010-07-06 2016-03-10 Glaxosmithkline Biologicals S.A. Cationic oil-in-water emulsions
CA2804396C (en) 2010-07-06 2021-06-29 Novartis Ag Liposomes with lipids having an advantageous pka-value for rna delivery
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
SI3981427T1 (sl) 2010-08-31 2022-08-31 Glaxosmithkline Biologicals S.A. Pegilirani liposomi za dostavo imunogen-kodirajoče RNA
RS63890B1 (sr) 2010-08-31 2023-02-28 Glaxosmithkline Biologicals Sa Mali lipozomi za isporuku rnk koja kodira imunogen
US20130189351A1 (en) 2010-08-31 2013-07-25 Novartis Ag Lipids suitable for liposomal delivery of protein coding rna
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
ES2888231T3 (es) 2010-09-20 2022-01-03 Sirna Therapeutics Inc Lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos
EP2621480B1 (en) 2010-09-30 2018-08-15 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
EP3485913A1 (en) 2010-10-21 2019-05-22 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
US20150056300A1 (en) 2010-10-22 2015-02-26 Bind Therapeutics, Inc. Therapeutic nanoparticles with high molecular weight copolymers
EP2635265B1 (en) 2010-11-05 2018-04-04 Sirna Therapeutics, Inc. Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
WO2012068176A1 (en) 2010-11-15 2012-05-24 Life Technologies Corporation Amine-containing transfection reagents and methods for making and using same
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
WO2013014073A1 (en) 2011-07-22 2013-01-31 Universite De Strasbourg Phospholipid-detergent conjugates and uses thereof
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
US9126966B2 (en) 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
WO2013049328A1 (en) 2011-09-27 2013-04-04 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
DK2768958T3 (da) 2011-10-18 2019-09-16 Dicerna Pharmaceuticals Inc Kationiske aminlipider og anvendelser deraf
JP2013095755A (ja) * 2011-11-02 2013-05-20 Kyowa Hakko Kirin Co Ltd カチオン性脂質
EP2788006A1 (en) 2011-12-07 2014-10-15 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
CA2856737C (en) 2011-12-07 2023-09-26 Alnylam Pharmaceuticals, Inc. Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
WO2013086373A1 (en) * 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
EP2623121A1 (en) 2012-01-31 2013-08-07 Bayer Innovation GmbH Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
AU2013222179B2 (en) 2012-02-24 2017-08-24 Arbutus Biopharma Corporat ion Trialkyl cationic lipids and methods of use thereof
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
RU2660565C2 (ru) 2012-03-27 2018-07-06 Кьюрвак Аг Молекулы искусственной нуклеиновой кислоты, содержащие 5'utr гена top
EP2831239B1 (en) 2012-03-27 2017-11-22 CureVac AG Artificial nucleic acid molecules
DK2830594T3 (en) 2012-03-27 2018-08-13 Sirna Therapeutics Inc DIETHER-BASED BIOLOGICALLY DEGRADABLE CATIONIC LIPIDS FOR siRNA RELEASE
RU2750261C2 (ru) 2012-03-27 2021-06-25 Кьюрвак Аг Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков и пептидов
US20150306249A1 (en) 2012-05-25 2015-10-29 Curevac Gmbh Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
US9415109B2 (en) 2012-07-06 2016-08-16 Alnylam Pharmaceuticals, Inc. Stable non-aggregating nucleic acid lipid particle formulations
CA2884870C (en) 2012-08-13 2022-03-29 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
US9687448B2 (en) 2012-12-07 2017-06-27 Alnylam Pharmaceuticals, Inc. Nucleic acid lipid particle formulations
SG10201710472PA (en) 2013-02-22 2018-02-27 Curevac Ag Combination of vaccination and inhibition of the pd-1 pathway
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
WO2014160284A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of stroke
CA2906110C (en) 2013-03-14 2021-07-27 Dicerna Pharmaceuticals, Inc. Process for formulating an anionic agent
US9693958B2 (en) 2013-03-15 2017-07-04 Cureport, Inc. Methods and devices for preparation of lipid nanoparticles
RU2712743C2 (ru) 2013-08-21 2020-01-30 Куревак Аг Вакцина против бешенства
MX2016002153A (es) 2013-08-21 2017-03-01 Curevac Ag Composicion y vacuna para tratar cancer de prostata.
CN105473157A (zh) 2013-08-21 2016-04-06 库瑞瓦格股份公司 组合疫苗
WO2015024667A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Method for increasing expression of rna-encoded proteins
CA2915728A1 (en) 2013-08-21 2015-02-26 Thomas Kramps Respiratory syncytial virus (rsv) vaccine
CA2925021C (en) 2013-11-01 2025-05-06 Curevac Ag MODIFIED MESSENGER RIBONUCLE ACID (MRNA) WITH REDUCED IMMUNOSTIMULATING PROPERTIES
AU2014348212C1 (en) 2013-11-18 2018-11-29 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
AU2014375402B2 (en) 2013-12-30 2020-10-01 CureVac SE Artificial nucleic acid molecules
JP6584414B2 (ja) 2013-12-30 2019-10-02 キュアバック アーゲー 人工核酸分子
US20170042870A1 (en) 2014-02-17 2017-02-16 The Brigham And Women's Hospital, Inc. Targeted nanoparticle compositions and methods of their use to treat obesity
WO2015130584A2 (en) 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
US10369216B2 (en) 2014-04-01 2019-08-06 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
WO2015164421A1 (en) 2014-04-21 2015-10-29 The Trustees Of Columbia University In The City Of New York Human movement research, therapeutic, and diagnostic devices, methods, and systems
ES3009962T3 (en) 2014-04-23 2025-03-31 Modernatx Inc Nucleic acid vaccines
CN106537012B (zh) 2014-05-22 2019-02-12 福斯有限责任公司 用于阀致动器的引导元件和设置有所述引导元件的致动器
CN106795096B (zh) 2014-06-25 2020-05-29 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
WO2016010840A1 (en) 2014-07-16 2016-01-21 Novartis Ag Method of encapsulating a nucleic acid in a lipid nanoparticle host
JP6339884B2 (ja) 2014-07-17 2018-06-06 富士フイルム株式会社 イミダゾール化合物およびそれを含有するリポソーム
WO2016014794A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
EP3230458B1 (en) 2014-12-12 2020-02-19 CureVac AG Artificial nucleic acid molecules for improved protein expression
EP3233113A1 (en) 2014-12-16 2017-10-25 CureVac AG Ebolavirus and marburgvirus vaccines
CA2966092A1 (en) 2014-12-30 2016-07-07 Curevac Ag Artificial nucleic acid molecules
CN104876831B (zh) 2015-04-03 2017-05-17 苏州圣诺生物医药技术有限公司 脂质修饰精胺衍生物及利用该衍生物制备的脂质体
EP3283059B1 (en) 2015-04-13 2024-01-03 CureVac Manufacturing GmbH Method for producing rna compositions
EP3289083A4 (en) * 2015-04-27 2018-12-19 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
ES2875589T3 (es) 2015-05-15 2021-11-10 Curevac Ag Regímenes de sensibilización-refuerzo que implican la administración de al menos un constructo de ARNm
US20180296663A1 (en) 2015-06-17 2018-10-18 Curevac Ag Vaccine composition
HRP20240865T1 (hr) 2015-06-29 2024-10-11 Acuitas Therapeutics Inc. Lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina
EP3331555A1 (en) 2015-08-05 2018-06-13 CureVac AG Epidermal mrna vaccine
DK3332019T3 (da) 2015-08-07 2020-02-17 Curevac Ag Fremgangsmåde til in vivo-produktionen af rna i en værtscelle
KR102645398B1 (ko) 2015-08-28 2024-03-07 큐어백 에스이 신규 인공 핵산 분자
WO2017048770A1 (en) 2015-09-15 2017-03-23 Regulus Therapeutics, Inc. Systems, compositions, and methods for formulating nucleic acid compositions
ES2910425T3 (es) 2015-09-17 2022-05-12 Modernatx Inc Compuestos y composiciones para la administración intracelular de agentes terapéuticos
AU2016343803B2 (en) 2015-10-28 2021-04-29 Acuitas Therapeutics, Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
US20180312545A1 (en) 2015-11-09 2018-11-01 Curevac Ag Optimized nucleic acid molecules
WO2017081110A1 (en) 2015-11-09 2017-05-18 Curevac Ag Rotavirus vaccines
SMT202200252T1 (it) 2015-12-22 2022-07-21 Modernatx Inc Composti e composizioni per il rilascio intracellulare di agenti
US20190022247A1 (en) 2015-12-30 2019-01-24 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US11723967B2 (en) 2016-02-17 2023-08-15 CureVac SE Zika virus vaccine
US20170266292A1 (en) 2016-03-21 2017-09-21 The Research Foundation For The State University Of New York Lipidic compound-telodendrimer hybrid nanoparticles and methods of making and uses thereof
CN109475646A (zh) 2016-03-30 2019-03-15 因特利亚治疗公司 用于crispr/cas成分的脂质纳米颗粒制剂
EP3445392A1 (en) 2016-04-22 2019-02-27 CureVac AG Rna encoding a tumor antigen
US20180126003A1 (en) 2016-05-04 2018-05-10 Curevac Ag New targets for rna therapeutics
ES2871537T3 (es) 2016-05-09 2021-10-29 Astrazeneca Ab Nanopartículas lipídicas que comprenden agentes antiinflamatorios lipófilos y métodos de uso de las mismas
US20190298657A1 (en) 2016-05-18 2019-10-03 Modernatx, Inc. Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
MX2019004913A (es) 2016-10-26 2019-09-16 Curevac Ag Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
EP3532103B1 (en) 2016-10-26 2025-12-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
US20190274968A1 (en) 2016-10-27 2019-09-12 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
WO2018107026A1 (en) 2016-12-09 2018-06-14 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
EP3568480A1 (en) 2017-01-13 2019-11-20 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating nfkb2 expression
WO2018164674A1 (en) 2017-03-07 2018-09-13 Pleasant Anthem Automated postal delivery notification based on geolocation
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
WO2018191719A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipid delivery of therapeutic agents to adipose tissue
EP4410317A3 (en) 2017-04-28 2024-10-30 Acuitas Therapeutics Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3668834B1 (en) 2017-08-17 2024-10-02 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019089828A1 (en) 2017-10-31 2019-05-09 Acuitas Therapeutics, Inc. Lamellar lipid nanoparticles
IL322436A (en) 2018-09-21 2025-09-01 Acuitas Therapeutics Inc Systems and methods for producing lipid nanoparticles and liposomes
EP3867225A1 (en) 2018-10-18 2021-08-25 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
US11453639B2 (en) 2019-01-11 2022-09-27 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
FI4182297T3 (fi) 2020-07-16 2025-12-05 Acuitas Therapeutics Inc Kationisia lipidejä käytettäväksi lipidinanohiukkasissa

Also Published As

Publication number Publication date
IL277448B (en) 2022-02-01
IL289934B (en) 2022-12-01
JP6957573B2 (ja) 2021-11-02
US9738593B2 (en) 2017-08-22
EP4148083A1 (en) 2023-03-15
EP3160938B1 (en) 2020-09-16
RS63848B1 (sr) 2023-01-31
JP2022008909A (ja) 2022-01-14
LT3766916T (lt) 2023-01-10
US20250034081A1 (en) 2025-01-30
WO2015199952A1 (en) 2015-12-30
EP3766916A1 (en) 2021-01-20
IL298516B1 (en) 2024-11-01
IL298516A (en) 2023-01-01
SI3766916T1 (sl) 2023-01-31
US20150376115A1 (en) 2015-12-31
IL277448A (en) 2020-11-30
AU2015280499A1 (en) 2017-02-09
JP2025111544A (ja) 2025-07-30
EP3160938A1 (en) 2017-05-03
CN106795096A (zh) 2017-05-31
SMT202200502T1 (it) 2023-01-13
IL249718A0 (en) 2017-02-28
JP2019218403A (ja) 2019-12-26
PL3766916T3 (pl) 2023-02-27
AU2022200794A1 (en) 2022-02-24
US20170283367A1 (en) 2017-10-05
AU2015280499B2 (en) 2020-03-19
US20170157268A1 (en) 2017-06-08
US20210107861A1 (en) 2021-04-15
IL298516B2 (en) 2025-03-01
US10723692B2 (en) 2020-07-28
JP6594421B2 (ja) 2019-10-23
US11634379B2 (en) 2023-04-25
IL260772B (en) 2020-10-29
CN106795096B (zh) 2020-05-29
AU2020204111B2 (en) 2021-11-11
CA2953341C (en) 2023-01-24
JP2023055841A (ja) 2023-04-18
US20190270697A1 (en) 2019-09-05
ES2834556T3 (es) 2021-06-17
AU2024202770A1 (en) 2024-05-16
IL316479A (en) 2024-12-01
CA2953341A1 (en) 2015-12-30
CN111454165A (zh) 2020-07-28
HUE060907T2 (hu) 2023-04-28
US9737619B2 (en) 2017-08-22
JP7221353B2 (ja) 2023-02-13
US10106490B2 (en) 2018-10-23
AU2020204111A1 (en) 2020-07-09
IL289934A (en) 2022-03-01
PT3766916T (pt) 2022-11-28
CN111454165B (zh) 2024-01-05
EP3766916B1 (en) 2022-09-28
HRP20221536T1 (hr) 2023-02-17
JP2017522376A (ja) 2017-08-10
AU2022200794B2 (en) 2024-02-08
CA3179824A1 (en) 2015-12-30
ES2931832T3 (es) 2023-01-03

Similar Documents

Publication Publication Date Title
AU2022200794B2 (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
US12151996B2 (en) Lipids for lipid nanoparticle delivery of active agents
US20220204439A1 (en) Lipids and lipid nanoparticle formulations for delivery of nucleic acids
IL258501A (en) New lipids and nanoparticles of lipids to give nucleic acids
HK40090394A (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
HK40045790A (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
HK40045790B (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
US20250236586A1 (en) Lipids for lipid nanoparticle delivery of active agents
HK1240206A1 (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
HK1240206B (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids